Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 15;17:355–370. doi: 10.2147/COPD.S342357

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Price et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Density plots showing the distribution of propensity scores for patients treated with extrafine particle fixed dose beclometasone (ef-FDC-BDP) and fine-particle fixed dose fluticasone (fp-FDC-F). The propensity score represents the estimated probability that each patient is assigned to fp-FDC-F treatment, based on their baseline characteristics (with possible values ranging from 0 to 1). A rug plot is shown along the x-axis, with a circle representing the propensity score for each patient, providing a compact visualisation of the range of propensity score values for each treatment (range of propensity scores for ef-FDC-BDP: 0.09–0.94; range of propensity scores for fp-FDC-F: 0.12–0.96).

Abbreviation: FDC, fixed dose combination.